TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study 301: BLI4900 Versus an FDA-approved Comparator in Adult Subjects Prior to Colonoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female outpatients who are undergoing colonoscopy for a routinely accepted indication.~* 18 to 85 years of age (inclusive)~* If female, and of child-bearing potential, is using an acceptable form of birth control.~* Negative serum pregnancy test at screening, if applicable~* In the Investigator's judgment, subject is mentally competent to provide informed consent to participate in the study~Exclusion Criteria:~* Subjects with known or suspected ileus, gastrointestinal obstruction, gastroparesis, gastric retention, bowel perforation, toxic colitis or megacolon.~* Subjects with inflammatory bowel disease who have a history of any bowel resection (small intestine or colon), suspected active inflammation, or symptoms suggestive of obstruction or known bowel stricture.~* Subjects who had previous significant gastrointestinal surgeries.~* Subjects who have regularly used laxatives or colon motility altering drugs in the last month (i.e. more than 2-3 times per week) and/or laxative use within 72 hours prior to administration of the preparation~* Subjects with uncontrolled pre-existing electrolyte abnormalities, or those with clinically significant electrolyte abnormalities based on Visit 1 laboratory results.~* Subjects taking diuretics, anti-hypertensive medications, including angiotensin converting enzyme (ACE) inhibitors and Angiotensin II receptor blockers (ARBs), or chronic NSAIDs, that have not been stable for 30 days.~* Subjects with uncontrolled hypertension.~* Subjects taking antibiotics within 7 days of colonoscopy.~* Subjects with severe renal, hepatic or cardiac insufficiency.~* Subjects with an abnormal and clinically significant physical examination or ECG finding at Visit 1.~* Subjects undergoing insulin therapy for any indication.~* Subjects with impaired consciousness that predisposes them to pulmonary aspiration.~* Subjects undergoing colonoscopy for foreign body removal and/or decompression.~* Subjects taking tricyclic antidepressants.~* Subjects using drugs of abuse, including abused prescription medications.~* Subjects who are withdrawing from alcohol or benzodiazepines.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- BLI4900 (Type: EXPERIMENTAL): Experimental bowel preparation solution for oral ingestion
- FDA Approved Control (Type: ACTIVE_COMPARATOR): FDA approved bowel preparation solution for oral ingestion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Levofloxacin-based Concomitant Therapy for H. Pylori Eradication in Diabetic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diabetic patients with Helicobacter pylori infection~Exclusion Criteria:~* Pregnancy or physically poor performance status~* Patients with contraindication for upper endoscopy~* Severe coagulopathy for endoscopic biopsy~* Chronic kidney disease (eGFR \< 50) or end stage renal disease~* Known allergy to interventional drugs~* Previous eradication failure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Levofloxacin-based concomitant (Type: EXPERIMENTAL): Pantoprazole 40 mg BID day1\~day10 Amoxicillin 1000 mg BID day1\~day10 Metronidazole 500 mg BID day1\~day10 Levofloxacin 500 mg QD day1\~day10
- Sequential (Type: ACTIVE_COMPARATOR): Pantoprazole 40 mg BID day1\~day10 Amoxicillin 1000 mg BID day1\~day5 Metronidazole 500 mg BID day6\~day10 Clarithromycin 500 mg BID day6\~day10

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Priming Effects by PLAI Vaccine on the Subsequent Response to Inactivated H5N1 Vaccine

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participated in the Phase II study Protocol No.: GPO AVIAN FLU Vaccine-V02-2~* Healthy~* Age 18-49 years old~* Having Thai ID card or equivalent~* Anti HIV - Negative~* All hematology, biochemistry and urine analysis are within normal range or of no clinical significance (not higher than 1.5 time of normal value without any clinical finding from history and physical examination)~* Able to read and write and sign written informed consent.~Exclusion Criteria:~* Known history of egg allergy~* Having had recently influenza infection confirmed as H5~* Receiving other vaccination against H5N1~* History of bronchial asthma~* History of chronic lung diseases~* History of chronic rhinitis~* History of immunodeficiency state~* History of immunosuppression\< 6 months prior to immunization~* History of heavy smoking (more than 5 packs per day)~* History of alcoholic (pure drink 200 ml per day)~* Acute infectious and noninfectious diseases (within 2 weeks)~* HIV positives~* The volunteers who have been taking immunoglobulin products or have had a blood transfusion during past three months before the beginning of the experiment~* Participation in other research study or stop participant less than 1 month~* Pregnancy or plan to become pregnant for 60 days after enrollment or breast feeding~* Poultry workers

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: t

Study Arms:
- OrniFlu® inactivated vaccine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Role of Endothelin in Microvascular Dysfunction Following PCI for NSTEMI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* Clinical diagnosis of unstable angina or non ST-elevation myocardial infarction, and requiring clinically indicated PCI for the management of non ST elevation acute coronary syndrome.~Exclusion Criteria:~* Systemic hypotension (systolic \<90 mmHg)~* Heart failure or known ejection fraction \< 30%~* Left main disease~* Culprit lesion is in a saphenous vein graft~* 100% occlusion of the culprit vessel or culprit is an ostial right coronary stenosis~* Currently enrolled in other active cardiovascular investigational studies~* Severe endocrine, hepatic, or renal disorders~* Pregnancy or lactation~* Federal Medical Center inmates~* Inability or unwillingness to provide informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BQ-123 (Type: EXPERIMENTAL): BQ-123 will be infused at 300 nmol/min for 20 minutes prior to percutaneous coronary intervention (PCI).
- Placebo (Type: PLACEBO_COMPARATOR): Subjects randomized to the placebo arm will receive a placebo infusion (saline) for 20 minutes prior to PCI.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating A 13-Valent Pneumococcal Conjugate Vaccine Administered To Infants In Korea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy 2-month-old-infants (42 to 98 days)~* Available for the entire study period (14 months)~Exclusion Criteria:~* Previous vaccine with pneumococcal, diptheria, tetanus, pertussis, polio or Hib vaccine~* A previous severe reaction to any vaccine or vaccine-related component

- Gender: ALL
- Minimum Age: 42 Days
- Maximum Age: 98 Days
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): 13vPnC
- 2 (Type: ACTIVE_COMPARATOR): 7vPnC

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects From 2 Months to 55 Years of Age in the Republic of South Korea

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Individuals eligible for enrolment in this study are those:~1. male and female subjects from 2 months to 55 years of the age at the time of Visit 1 (including all 55 years old subjects, up to one day before their 56th year birthday), who are scheduled to receive vaccination with MenACWY-CRM conjugate vaccine, according to the local prescribing information and routine clinical practice;~2. to whom the nature of the study has been described and the subject or subject's parent/legal representative has provided written informed consent;~3. whom the investigator believes that the subject can and will comply with the requirements of the protocol (e.g., completion of the Diary Card);~4. who are in good health as determined by the outcome of medical history, physical assessment and clinical judgment of the investigator.~Exclusion Criteria:~1. Contraindication, special warnings and/or precautions, as evaluated by the investigators, reported in the MenACWY-CRM conjugate vaccine Korean prescribing information. In particular, should not be included in the study a subject who has ever had:~* an allergic reaction to the active substances or any of the other ingredients of the study vaccine; an allergic reaction to diphtheria toxoid;~* an illness with high fever; however, a mild fever or upper respiratory infection (for example cold) itself is not a reason to delay vaccination. Special care should be taken for subjects having haemophilia or any other problem that may stop your blood from clotting properly, such as persons receiving blood thinners (anticoagulants).

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- MenACWY-CRM Group (Type: EXPERIMENTAL): Healthy subjects from 2 months to 55 years of age in South Korea, who received MenACWY-CRM (Menveo) vaccination, according to routine clinical care.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary Angioedema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Type I or Type II HAE.~* History of angioedema attacks.~Exclusion Criteria:~* History of bleeding or clotting abnormality.~* Diagnosis of acquired angioedema or known to have C1 INH antibodies.~* History of allergic reaction to C1 esterase inhibitor or other blood products.~* Receipt of any experimental agents other than those required for prevention or treatment of angioedema attacks within 30 days prior to screening.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- 500/1000 (Type: EXPERIMENTAL): 500 Units of CINRYZE administered by IV injection twice per week for 12 weeks followed by 1000 Units of CINRYZE administered by IV injection twice per week for 12 weeks
- 1000/500 (Type: EXPERIMENTAL): 1000 Units of CINRYZE administered by IV injection twice per week for 12 weeks followed by 500 Units of CINRYZE administered by IV injection twice per week for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: S-1 and Photodynamic Therapy in Cholangiocarcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Histologic or cytologic diagnosis of cholangiocarcinoma~* Not eligible for curative surgery~* Eastern Cooperative Oncology Group (ECOG) performance status of 2 or better~* No serious or uncontrolled concomitant medical illness~* Adequate bone marrow function (absolute neutrophil count ≧1,500 ul, platelet count ≧75,000/ul)~* Consent this study in letter~Exclusion Criteria:~* Another neoplasia~* Porphyria~* Pregnant or breastfeeding women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Treatment by combination of photodynamic therapy and S-1~1. PDT with Photofrin® 2mg/kg i.v. 48hrs before laser activation~2. S-1 chemotherapy before intolerable complication or definite tumor progression Based on the body surface area, \<1.25m2: 80mg/day, 1.25\~1.5m2: 100mg/day, ≧1.5m2: 120mg/day Given orally twice daily for 14days, followed by 7 days without treatment
- 2 (Type: ACTIVE_COMPARATOR): Treatment by photodynamic therapy only~1. PDT with Photofrin® 2mg/kg i.v. 48hrs before laser activation~2. Other managements except systemic chemotherapy were added freely.
- 3 (Type: OTHER): Treatment by photodynamic therapy only or combined chemotherapy with photodynamic therapy: Open label

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adults, Children, Older Infants and Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Main eligibility criteria:~* Subjects belonging to 4 age groups will be enrolled into the trial: adults (18 to 45 years of age), children (24 to 59 months of age), older infants (9 to 12 months of age at enrollment) and infants (6 weeks of age at enrolment).~* Written informed consent will be obtained by the all subjects or their parents/ guardians (depending on the age group) before enrollment into the trial.~* Only females with a negative pregnancy test and willing to participate in family planning consultations (organized by the site study team) will be allowed to participate to the trial.~* Infants who have been vaccinated with 1 dose of BCG, HBV and OPV at birth can be enrolled into the trial, while infants who have received DTwP+HBV+Hib or OPV due at 6 weeks of age as per local EPI schedule cannot be enrolled into the trial.

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Vi-CRM, Adults (Type: EXPERIMENTAL): Adults (18 to 45 years) receiving 1 dose of NVGH Vi-CRM197 vaccine
- Vi-PS, Adults (Type: ACTIVE_COMPARATOR): Adults (18 to 45 years) receiving 1 dose of licensed Vi Polysaccharide vaccine
- Vi-CRM, Children (Type: EXPERIMENTAL): Children (24 to 59 months) receiving 2 doses of NVGH Vi-CRM197 vaccine
- Vi-PS, Children (Type: ACTIVE_COMPARATOR): Children (24 to 59 months) receiving 1 dose of licensed Vi Polysaccharide vaccine and 1 dose of Pneumococcal conjugate vaccine
- Vi-CRM, Older infants (Type: EXPERIMENTAL): Older Infants (9 to 12 months) receiving 2 doses of NVGH Vi-CRM197 vaccine
- PNC13, Older infants (Type: ACTIVE_COMPARATOR): Older Infants (9 to 12 months) receiving 2 doses of Pneumococcal conjugate vaccine
- Vi-CRM, Infants (Type: EXPERIMENTAL): Infants (6 to 8 weeks) receiving 3 doses of NVGH Vi-CRM197 vaccine
- PNC13, Infants (Type: ACTIVE_COMPARATOR): Infants (6 to 8 weeks) receiving 3 doses of Pneumococcal conjugate vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Empagliflozin Kinetics on Renal Glucose Reabsorption in Patients With Type II Diabetes and Healthy Controls

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. T2DM patients and healthy controls aged =18 to \<70 at Visit 1.~2. Patients diagnosed with T2DM according to the American Diabetes Association criteria prior to informed consent who are drug-naïve~3. T2DM patients on a stable dose of allowed concomitant medications (as determined by investigator) for 30 days prior to entering the study.~4. T2DM patients with HbA1c between \>7 and \<10.0% (\>53 mmol/mol and \<86 mmol/mol) at Visit~Exclusion criteria:~1. Patients with type 1 diabetes mellitus.~2. Patients with uncontrolled hyperglycemia with a fasting plasma glucose level greater than 240 mg/dl after an overnight fast.~3. Patients with a history of clinically significant heart disease (New York Heart Classification greater than class 3; more than non-specific ST-T wave changes on the ECG), peripheral vascular disease (history of claudication), or pulmonary disease as determined by investigator.~4. Medical history of cancer (except for basal cell carcinoma) and/or treatment for cancer within the last 5 years.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Healthy Controls (Type: EXPERIMENTAL): healthy controls
- Patients (Type: EXPERIMENTAL): patients with type 2 diabetes mellitus

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prediction of Postsurgical Symptomatic Outcomes With Preoperative Pessary Use

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Older than 18 years of age~* With symptomatic pelvic organ prolapse~* Electing for surgical repair of pelvic organ prolapse (transvaginal or transabdominal) at least 7 days after office consultation~* Understand and have signed written informed consent for preoperative pessary placement.~Exclusion Criteria:~* Previous use of a pessary for pelvic organ prolapse~* Patients undergoing obliterative prolapse surgery (i.e. Colpocleisis),~* Are scheduled for surgery for pelvic organ prolapse less than 7 days after office consultation or greater than 4 weeks after office consultation~* Have an isolated rectocele~* Have allergies to both latex and silicone~* Have an active pelvic infection

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Preoperative Pessary Use (Type: EXPERIMENTAL): All patients will use a pessary for 1-4 weeks preoperatively to reparative surgery for pelvic organ prolapse

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of HCP1102 Capsule

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion:~* Age≥15~* Mild or moderate asthma patients with allergic rhinitis~* Patient who meet all criteria of rhinitis~* Patients understood the contents and purpose of this trial and signed informed consent form~* Patients who are capable and willing to write subject diary~* Patients who agree with maintain same environment during clinical trials~Exclusion:~* Nonallergic rhinitis~* Severe asthma~* Other pulmonary disease (pulmonary tuberculosis, COPD) except Asthma~* Medical history of hypertrophic cardiomyopathy, cancer, renal disease, Liver disease, cardiovascular disease, respiratory disease, endocrine disorder, CNS disorder that effect safety~* Medical history of gastrointestinal surgery or gastrointestinal disorders that effect drug absorption~* Alcohol abuse or Drug abuse~* Genetic factor of galactose intolerance or Lapp lactase deficiency or glucose-galactose malabsorption~* pregnant or breast-feeding women or men/women of childbearing age that they don't use contraceptives~* Patient who administered other investigational products within 30 days~* Current smoker Judged to be inappropriate for the study by the investigator after reviewing other reasons

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HCP1102+HGP0711Placebo (Type: EXPERIMENTAL): HCP1102Placebo+HGP0711Placebo(1week) -\> HCP1102+HGP0711Placebo(4weeks) Each 1 capsule, once daily
- HCP1102Placebo+HGP0711 (Type: ACTIVE_COMPARATOR): HCP1102Placebo+HGP0711Placebo(1week) -\> HCP1102Placebo+HGP0711(4weeks) Each 1 capsule, once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Perioperative Pain Control With Celecoxib (Celebrex) in Total Knee Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients receiving total knee replacement will be recruited in this study.~Exclusion Criteria:~* subjects with end-stage renal disease, cerebral vascular accident, peptic ulcer, long-term usage of NSAIDs.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Celecoxib (Celebrex)
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete